Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yutaka Tokuda

Showing results (81-90 of 121) with videos related to

Pageof 13
Sort By:
International Journal of Clinical Oncology|May 16, 2012
A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxaneYasuhiro Suzuki, Toshiaki Saeki, Kenjiro Aogi, et al.
Breast Cancer (Tokyo, Japan)|April 18, 2022
Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trialHitoshi Tsuda, Masafumi Kurosumi, Futoshi Akiyama, et al.
Experimental Hematology|September 10, 2003
Functional CD5+ B cells develop predominantly in the spleen of NOD/SCID/gammac(null) (NOG) mice transplanted either with human umbilical cord blood, bone marrow, or mobilized peripheral blood CD34+ cellsTakuya Matsumura, Yoshie Kametani, Kiyoshi Ando, et al.
Breast Cancer (Tokyo, Japan)|July 1, 2018
Comparison of Ki-67 labeling index measurements using digital image analysis and scoring by pathologistsToru Morioka, Naoki Niikura, Nobue Kumaki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 TrialToru Watanabe, Muneaki Sano, Shigemitsu Takashima, et al.
Clinical Breast Cancer|February 5, 2014
Prognostic significance of the Ki67 scoring categories in breast cancer subgroupsNaoki Niikura, Shinobu Masuda, Nobue Kumaki, et al.
Breast Cancer Research and Treatment|December 1, 2020
Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N·SAS-BC 01 trial and CUBC trial)Shinji Ohno, Shigehira Saji, Norikazu Masuda, et al.
Clinical Breast Cancer|December 14, 2011
Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancerSeigo Nakamura, Masashi Ando, Norikazu Masuda, et al.
Anticancer Research|October 4, 2011
Antitumor effect of new HER2 peptide vaccination based on B cell epitopeHirohito Miyako, Yoshie Kametani, Ikumi Katano, et al.
Breast Cancer Research and Treatment|September 15, 2017
Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancerMariko Kochi, Takayuki Iwamoto, Naoki Niikura, et al.
Pageof 13

Showing results (81-90 of 121) with videos related to

Sort By:
Pageof 13
International Journal of Clinical Oncology|May 16, 2012
A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxaneYasuhiro Suzuki, Toshiaki Saeki, Kenjiro Aogi, et al.
Breast Cancer (Tokyo, Japan)|April 18, 2022
Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trialHitoshi Tsuda, Masafumi Kurosumi, Futoshi Akiyama, et al.
Experimental Hematology|September 10, 2003
Functional CD5+ B cells develop predominantly in the spleen of NOD/SCID/gammac(null) (NOG) mice transplanted either with human umbilical cord blood, bone marrow, or mobilized peripheral blood CD34+ cellsTakuya Matsumura, Yoshie Kametani, Kiyoshi Ando, et al.
Breast Cancer (Tokyo, Japan)|July 1, 2018
Comparison of Ki-67 labeling index measurements using digital image analysis and scoring by pathologistsToru Morioka, Naoki Niikura, Nobue Kumaki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 TrialToru Watanabe, Muneaki Sano, Shigemitsu Takashima, et al.
Clinical Breast Cancer|February 5, 2014
Prognostic significance of the Ki67 scoring categories in breast cancer subgroupsNaoki Niikura, Shinobu Masuda, Nobue Kumaki, et al.
Breast Cancer Research and Treatment|December 1, 2020
Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N·SAS-BC 01 trial and CUBC trial)Shinji Ohno, Shigehira Saji, Norikazu Masuda, et al.
Clinical Breast Cancer|December 14, 2011
Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancerSeigo Nakamura, Masashi Ando, Norikazu Masuda, et al.
Anticancer Research|October 4, 2011
Antitumor effect of new HER2 peptide vaccination based on B cell epitopeHirohito Miyako, Yoshie Kametani, Ikumi Katano, et al.
Breast Cancer Research and Treatment|September 15, 2017
Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancerMariko Kochi, Takayuki Iwamoto, Naoki Niikura, et al.
Pageof 13